Notice of Intent to Sole Source - Metrohm - i-Raman NXG 785 S system
CDC · CDC OFFICE OF ACQUISITION SERVICES
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 98646 in this department, oldest first.
- Aug 25, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
This request is for the purchase of a Metrohm i-Raman NXG 785 S system which is a commercial off the shelf (COTS), portable Raman instrument. This acquisition replaces an obsolete, unrepairable Raman spectrometer (from B&W Tek, now owned by Metrohm) to prevent loss of critical analytical capability supporting NMAM method publication and implementation. Modern Raman technology improves sensitivity, reliability, and serviceability while maintaining portability for field-relevant applications. Additionally, this request is for the purchase of one ?Stat-i M8ONE (Bi)potentiostat/Galvanostat/Impedan… (show all)
ce Analyzer (EIS). This instrument will support CBMB researchers in ongoing dermal penetration studies using Franz cells by measuring impedance across skin membranes and generating high-quality graphs for publications and presentations. It will replace a single-channel unit and enable researchers to perform up to 16 simultaneous experiments instead of one at a time, significantly reducing experiment time and accelerating the delivery of results. Additional cables and training are provided as part of the package. The vendor will install the instrument, ensure correct operation, and train operators onsite for one day (i-Raman NXG) and 4 hours and online (?Stat-i M8ONE EIS) as needed. An existing CDC laboratory desktop connected to the ISLE (CDC Property # 357548) will be used to operate the i-Raman NXG 785 S instrument using the SpecSuite software. The NIOSH request for level III approval for the SpecSuite software has been submitted. The ?Stat-i M8ONE EIS instrument runs on DropView software which the laboratory possesses currently, but may require an upgrade. It will not require any additional external computer system for operation. The instrument is designated for laboratory use only and will be connected to the current ISLE system.
Who won similar work
111 award notices on SAM.gov in the last 24 months. Matched by: Same agency (CDC), any industry: a loose match.
Loose match: same agency, any industry. Read the titles before treating these as competitors.
Single-winner award sizes (111): middle half $247K to $9.0M, median $992K; range $14K to $4.5B.
| Winner | Awards | Value | Last |
|---|---|---|---|
| POLOLEI SOLUTIONS, LLC | 5 | $3.3M | Jul 21, 2026 |
| GLAXOSMITHKLINE, LLC | 3 | $1.7B | Mar 27, 2026 |
| RESEARCH TRIANGLE INSTITUTE Durham NC 27709 USA | 3 | $9.8M | Jun 4, 2026 |
| MERCK SHARP & DOHME LLC · $MRK · $60.1B | 2 | $4.5B | Sep 14, 2026 |
| Pfizer New York NY 10001 USA | 2 | $1.2B | Jun 3, 2026 |
| SEQIRUS USA INC | 2 | $663.9M | Dec 31, 2024 |
| Moderna Princeton NJ 08540 USA | 2 | $314.2M | Jun 3, 2026 |
| SANOFI PASTEUR INC. | 2 | $233.3M | Dec 31, 2024 |
| AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA | 2 | $155.3M | May 18, 2026 |
| ASTRAZENECA PHARMACEUTICALS LP | 2 | $61.0M | Dec 31, 2024 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $MRK reported $60.1B revenue in FY2025. The median single-winner award in these 111 past awards, $992K, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Sep 28, 2026SPN SOLUTIONS INC$992KModernized VAERS Reporting ApplicationNo listed company matched (Materiality N/A)
- Sep 28, 2026PREMIER HEALTHCARE SOLUTIONS, INC$4.2MComprehensive Encounter-level Inpatient and Hospital-based Outpatient Billing and Chargemaster Database for Addressing Public Health PrioritiesNo listed company matched (Materiality N/A)
- Sep 21, 2026Precision Delivery Federal LLC$296KMarket forecast analyses for West Nile virus (WNV) vaccine and anti-WNV monoclonal antibody for prophylaxisNo listed company matched (Materiality N/A)
- Sep 15, 2026NEW TECH SOLUTIONS, INC.$195KNetwork Analysis ToolNo listed company matched (Materiality N/A)
- Sep 14, 2026MERCK SHARP & DOHME LLC$9.5MMerck Stockpile Vaccine Storage and Rotation ContractMateriality: 0.02% of $MRK revenue (Low) SEC
- Sep 11, 2026Johnson Controls Building Automation Systems, LLC$1.9MCCURE PACS Software Support Agreement (Smart Cards)No listed company matched (Materiality N/A)
- Sep 9, 2026DECISIONPOINT CORPORATION$28.1MDEO/ORR All Hazards Labor SupportNo listed company matched (Materiality N/A)
- Aug 31, 2026RELI GROUP INC$2.2MRisk Management Framework and Cloud Security Operations Support ServicesNo listed company matched (Materiality N/A)
- Aug 24, 2026BANYAN COMMUNICATIONS, INC.$2.5MDFWED Communication ServicesNo listed company matched (Materiality N/A)
- Jul 28, 2026MANHATTAN TORCON A JOINT VENTURE Arlington VA 22201 USA$491.8MConstruction of High-Containment Continuity Laboratory, Building 28 - CDC Roybal Campus, Atlanta, GANo listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Centers For Disease Control & Prevention (CDC) since 2024 (5 filings)
- 0 of their lobbyists list a past Centers For Disease Control & Prevention (CDC) job
- $99K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 1 of the past winners are listed companies
- 0 insider buys and 7 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.